Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 30
Filtrar
1.
J Pediatr Urol ; 17(5): 654.e1-654.e6, 2021 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-34266748

RESUMO

BACKGROUND: Children with congenital adrenal hyperplasia (CAH) are at risk for adrenal crises in the perioperative period and require higher doses of glucocorticoids. However, there are no specific protocols detailing the appropriate stress dosing required for children with CAH undergoing surgery with anesthesia. OBJECTIVE: To evaluate CAH patients using our current hydrocortisone stress dose surgical protocol. We hypothesized that current clinical protocols may overestimate the endogenous response to perioperative stress. STUDY DESIGN: 14 children with CAH scheduled to have genital surgery and a control group of 10 unaffected children scheduled to have cardiac or urologic surgery (of a similar duration) were evaluated in a prospective observational study. Urinary free cortisol (UFC) and urinary 17-hydroxycorticosteroids (17-OHCS) per body surface area were measured in the postoperative period. RESULTS: UFC levels were significantly higher in CAH patients (115.8 ± 24.6 nmol/m2) than in controls (26.5 ± 12.2 nmol/m2), P < 0.05.17-OHCS levels were also higher in CAH patients than in controls (6.5 ± 0.5 nmol/m2 vs. 3.4 ± 0.5 nmol/m2), P < 0.05). CONCLUSION: In the immediate postoperative period, urinary cortisol and its metabolites are significantly higher in pediatric CAH patients receiving stress dose corticosteroids compared to controls. Results suggest that the amount of hydrocortisone given during our stress dose protocol may be higher than physiologic needs. Future dynamic studies are needed to determine appropriate perioperative and postoperative cortisol requirements in pediatric CAH patients in order to develop optimal stress dose regimens.


Assuntos
Hiperplasia Suprarrenal Congênita , Doença Aguda , Hiperplasia Suprarrenal Congênita/tratamento farmacológico , Criança , Glucocorticoides , Humanos , Hidrocortisona , Estudos Prospectivos
2.
Horm Res Paediatr ; 84(3): 165-71, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26277904

RESUMO

BACKGROUND/AIMS: Factors in congenital adrenal hyperplasia (CAH) that may affect quality of life (QOL) include the need for lifelong medication, the risk of adrenal crisis, and hyperandrogenic symptoms. The objectives were to evaluate health-related QOL (HRQOL) in children with CAH, and whether CAH poses an additional burden compared to other endocrine disorders. METHODS: The validated PedsQL 4.0 generic core scales were administered to subjects (8-18 years) with CAH and hypothyroidism and their parents. The minimal clinically important difference (MCID) was determined for each scale score, allowing a comparison with the healthy population. A score of >1 standard deviation below the population mean was considered at risk for impaired HRQOL. RESULTS: In CAH, the mean total HRQOL scores were >1 MCID below the population mean, and a higher percentage than expected had scores considered at risk. CONCLUSION: Compared to subjects with hypothyroidism, subjects with CAH self-reported lower school domain scores. CAH subjects more frequently reported peers not wanting to be friends.


Assuntos
Hiperplasia Suprarrenal Congênita/psicologia , Qualidade de Vida , Adolescente , Criança , Emoções , Etnicidade , Feminino , Nível de Saúde , Humanos , Masculino , Pais , Grupo Associado , Instituições Acadêmicas , Comportamento Social
3.
J Pediatr Endocrinol Metab ; 27(5-6): 549-54, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24468605

RESUMO

BACKGROUND: Antiepileptics may affect cortisol metabolism through CYP3A4. There is little known about ethosuximide. CLINICAL CASE: Our patient is a 12-year-old girl with salt-wasting congenital adrenal hyperplasia (CAH) owing to 21 hydroxylase deficiency. A standard treatment regimen was initiated with satisfactory results until the age of 6 years, when she developed absence seizures treated with ethosuximide. She received such therapy until the age of 12 years, at which point ethosuximide was discontinued. During ethosuximide administration, she experienced worsening control of CAH disease activity that responded to progressive increases in hydrocortisone dose up to 28 mg/m2 per day. Despite high doses of hydrocortisone, she suffered no cushingoid symptoms. Her requirements for high glucocorticoid replacement doses resolved shortly after ethosuximide was discontinued. We provide data over 6 years demonstrating a correlation between adrenal hormone secretion, cortisol requirements and ethosuximide dose. CONCLUSION: This is the first case demonstrating an interaction between ethosuximide and hydrocortisone clearance in the treatment of salt-wasting CAH.


Assuntos
Hiperplasia Suprarrenal Congênita/tratamento farmacológico , Anti-Inflamatórios/metabolismo , Anti-Inflamatórios/uso terapêutico , Anticonvulsivantes/efeitos adversos , Etossuximida/efeitos adversos , Hidrocortisona/metabolismo , Hidrocortisona/uso terapêutico , Criança , Interações Medicamentosas , Epilepsia Tipo Ausência/complicações , Epilepsia Tipo Ausência/tratamento farmacológico , Epilepsia Tônico-Clônica/complicações , Epilepsia Tônico-Clônica/tratamento farmacológico , Feminino , Humanos
4.
Eur J Med Genet ; 56(11): 619-23, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24056159

RESUMO

Steroidogenic factor 1 (SF1) is a nuclear receptor encoded by the NR5A1 gene. SF1 affects both sexual and adrenal development through the regulation of target gene expression. Genotypic male and female SF1 knockout mice have adrenal and gonadal agenesis with persistent Müllerian structures and early lethality. There have been several reports of NR5A1 mutations in individuals with 46,XY complete gonadal dysgenesis (CGD) or other disorders of sex development (DSD) with or without an adrenal phenotype. To date microdeletions involving NR5A1 have been reported in only two patients with DSDs. We report a novel microdeletion encompassing NR5A1 in a patient with 46,XY DSD and developmental delay. The phenotypically female patient initially presented with mild developmental delay and dysmorphisms. Chromosome analysis revealed a 46,XY karyotype. A 1.54 Mb microdeletion of chromosome 9q33.3 including NR5A1 was detected by array CGH and confirmed by FISH. Normal maternal FISH results indicated that this was most likely a de novo event. Since most NR5A1 mutations have been ascertained through gonadal or adrenal abnormalities, the additional findings of developmental delay and minor facial dysmorphisms are possibly related to haploinsufficiency of other genes within the 1.54 Mb deleted region. This report further confirms the role of NR5A1 deletions in 46,XY DSD and reinforces the utility of aCGH in the work up of DSDs of unclear etiology.


Assuntos
Anormalidades Múltiplas/genética , Cromossomos Humanos Par 9/genética , Deficiências do Desenvolvimento/genética , Transtorno 46,XY do Desenvolvimento Sexual/genética , Deleção de Genes , Fator Esteroidogênico 1/genética , Anormalidades Múltiplas/diagnóstico , Criança , Deficiências do Desenvolvimento/diagnóstico , Transtorno 46,XY do Desenvolvimento Sexual/diagnóstico , Feminino , Humanos , Cariótipo , Síndrome
6.
J Pediatr Endocrinol Metab ; 25(5-6): 509-16, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22876547

RESUMO

BACKGROUND: Forty-three percent of New York City's (NYC) school-age children are overweight or obese, placing them at risk for heart disease and type 2 diabetes mellitus (T2DM). OBJECTIVE: The objective of this study was to determine if an intensive after-school dance and lifestyle education program would reduce risk factors for heart disease, T2DM, and improve lifestyle choices. SUBJECTS: Subject include 64 fourth- and fifth-grade students at an elementary school in NYC. METHODS: Students received freestyle dance and lifestyle classes for 16 weeks and were evaluated for changes in body composition, endurance, biochemical measurements, and lifestyle choices. RESULTS: Significant improvements in BMI percentiles were found among children in the overweight and obese categories as well as in endurance and biochemical measurements that reflect heart disease and diabetes risk. Improvement was also reported in lifestyle choices. CONCLUSION: An intensive after-school dance and lifestyle education program can reduce risk factors for heart disease and T2DM and improve lifestyle choices among elementary school children.


Assuntos
Dança/psicologia , Diabetes Mellitus Tipo 2 , Educação em Saúde/organização & administração , Promoção da Saúde/organização & administração , Cardiopatias , Estilo de Vida , Criança , Diabetes Mellitus Tipo 2/epidemiologia , Diabetes Mellitus Tipo 2/prevenção & controle , Diabetes Mellitus Tipo 2/psicologia , Feminino , Cardiopatias/epidemiologia , Cardiopatias/prevenção & controle , Cardiopatias/psicologia , Humanos , Masculino , Obesidade/epidemiologia , Obesidade/prevenção & controle , Obesidade/psicologia , Projetos Piloto , Avaliação de Programas e Projetos de Saúde , Estudos Prospectivos , Fatores de Risco , Serviços de Saúde Escolar/organização & administração
7.
Pediatr Clin North Am ; 58(5): 1281-300, xii, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21981961

RESUMO

Steroid 21 hydroxylase deficiency is the most common form of congenital adrenal hyperplasia (CAH). The severity of this disorder depends on the extent of impaired enzymatic activity, which is caused by various mutations of the 21 hydroxylase gene. This article reviews adrenal steroidogenesis and the pathophysiology of 21 hydroxylase deficiency. The three forms of CAH are then discussed in terms of clinical presentation, diagnosis and treatment, and genetic basis. Prenatal diagnosis and treatment are also reviewed. The goal of therapy is to correct the deficiency in cortisol secretion and suppress androgen overproduction. Glucocorticoid replacement has been the mainstay of treatment for CAH, but new treatment strategies continue to be developed and studied.


Assuntos
Hiperplasia Suprarrenal Congênita , Corticosteroides/uso terapêutico , Hiperplasia Suprarrenal Congênita/diagnóstico , Hiperplasia Suprarrenal Congênita/metabolismo , Hiperplasia Suprarrenal Congênita/terapia , Densidade Óssea , Feminino , Terapia de Reposição Hormonal , Humanos , Masculino , Técnicas de Diagnóstico Molecular , Gravidez , Complicações na Gravidez/terapia , Procedimentos de Cirurgia Plástica , Esteroide 21-Hidroxilase/metabolismo
10.
Ann N Y Acad Sci ; 1192: 5-11, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20392211

RESUMO

21-Hydroxylase deficiency is the most common cause of congenital adrenal hyperplasia (CAH), an inherited disorder of steroidogenesis. In its severe form, CAH causes genital ambiguity in females. Molecular genetic analysis of fetal DNA obtained by amniocentesis or chorionic villus sampling is used to diagnose steroid 21-OHD deficiency in utero. Large ongoing studies show that appropriate prenatal treatment of pregnant mothers with dexamethasone is effective and safe for both the fetus and the mother. It reduces ambiguous genitalia in the female affected fetus and thus avoids unnecessary genitoplasty in the newborn female.


Assuntos
Hiperplasia Suprarrenal Congênita/diagnóstico , Hiperplasia Suprarrenal Congênita/terapia , Diagnóstico Pré-Natal/métodos , Esteroide 21-Hidroxilase , Hiperplasia Suprarrenal Congênita/genética , Animais , Análise Mutacional de DNA , Feminino , Humanos , Modelos Biológicos , Gravidez , Cuidado Pré-Natal/métodos , Esteroide 21-Hidroxilase/genética
11.
Endocrinol Metab Clin North Am ; 38(4): 699-718, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19944288

RESUMO

Steroid 21 hydroxylase deficiency is the most common form of congenital adrenal hyperplasia (CAH). The severity of this disorder depends on the extent of impaired enzymatic activity, which is caused by various mutations of the 21 hydroxylase gene. This article reviews adrenal steroidogenesis and the pathophysiology of 21 hydroxylase deficiency. The three forms of CAH are then discussed in terms of clinical presentation, diagnosis and treatment, and genetic basis. Prenatal diagnosis and treatment are also reviewed. The goal of therapy is to correct the deficiency in cortisol secretion and suppress androgen overproduction. Glucocorticoid replacement has been the mainstay of treatment for CAH, but new treatment strategies continue to be developed and studied.


Assuntos
Hiperplasia Suprarrenal Congênita/diagnóstico , Hiperplasia Suprarrenal Congênita/genética , Hiperplasia Suprarrenal Congênita/fisiopatologia , Hiperplasia Suprarrenal Congênita/terapia , Adulto , Criança , Continuidade da Assistência ao Paciente , Feminino , Fertilidade/fisiologia , Humanos , Modelos Biológicos , Gravidez , Complicações na Gravidez/terapia , Esteroide 21-Hidroxilase/genética , Esteroide 21-Hidroxilase/metabolismo
12.
J Pediatr ; 155(5): 752-5.e1-3, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19840619

RESUMO

A 17-year-old boy with chromosomal mosaicism resulting in a 45,X/46,X,idic(Y)(p11) karyotype came to medical attention at the age of 10 years because of short stature. He was treated with recombinant growth hormone for 6.6 years and has achieved a near final adult height of 172.5 cm. His clinical features included second-degree hypospadias, some stigmata of Turner syndrome, and spontaneous progression through puberty. We report long-term use of growth hormone in a male adolescent with isodicentric Yq.


Assuntos
Estatura/efeitos dos fármacos , Transtornos do Crescimento/tratamento farmacológico , Hormônio do Crescimento Humano/uso terapêutico , Síndrome de Noonan/tratamento farmacológico , Adolescente , Aberrações Cromossômicas , Cromossomos Humanos X , Cromossomos Humanos Y , Relação Dose-Resposta a Droga , Esquema de Medicação , Seguimentos , Transtornos do Crescimento/diagnóstico , Transtornos do Crescimento/genética , Humanos , Hipospadia/diagnóstico , Hipospadia/cirurgia , Cariotipagem , Masculino , Síndrome de Noonan/diagnóstico , Fatores de Tempo , Resultado do Tratamento
13.
Mol Cell Endocrinol ; 300(1-2): 192-6, 2009 Mar 05.
Artigo em Inglês | MEDLINE | ID: mdl-19101608

RESUMO

Congenital adrenal hyperplasia (CAH) applies to a group of inherited disorders caused by an enzyme deficiency in steroid biosynthesis. The most common form of CAH is 21-hydroxylase deficiency (21-OHD), which in its severe form can cause genital ambiguity in females. Affected females experience virilization both physically and psychologically. Steroid 21-OHD can be diagnosed in utero through molecular genetic analysis of fetal DNA. Appropriate prenatal treatment by dexamethasone administration to the at-risk pregnant mother is effective in reducing genital virilization in the fetus, thus avoiding unnecessary genitoplasty in affected females. Current data from large human studies show that prenatal diagnosis and treatment are safe in the short term for both the fetus and the mother. Preliminary data from long-term studies support these results.


Assuntos
Hiperplasia Suprarrenal Congênita , Diagnóstico Pré-Natal/métodos , Hiperplasia Suprarrenal Congênita/diagnóstico , Hiperplasia Suprarrenal Congênita/enzimologia , Hiperplasia Suprarrenal Congênita/terapia , Androgênios/metabolismo , Feminino , Feto/fisiologia , Idade Gestacional , Humanos , Gravidez , Diferenciação Sexual , Esteroide 21-Hidroxilase/genética , Esteroide 21-Hidroxilase/metabolismo , Resultado do Tratamento
14.
Expert Rev Endocrinol Metab ; 4(1): 67-77, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30934374

RESUMO

Hyperandrogenism in congenital adrenal hyperplasia (CAH) results from overstimulation of adrenocorticotropic-driven androgen production in the adrenal cortex due to lack of cortisol feedback. The classical form is characterized by more-severe symptoms of hyperandrogenism, including virilization of the female genitalia. The milder nonclassical form presents with postnatal symptoms of hyperandrogenism. Presenting symptoms in adulthood may include acne, male-pattern alopecia, hirsutism, irregular menses/amenorrhea or infertility. The goal of therapy in CAH is to both correct the deficiency in cortisol secretion and suppress androgen overproduction. Glucocorticoid replacement has been the mainstay of treatment for CAH but new treatment strategies continue to be developed and studied.

15.
J Med Assoc Thai ; 91(10): 1544-50, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18972898

RESUMO

BACKGROUND: Adrenal insufficiency (AI) is an event caused by an inadequate secretion or action of adrenal hormones. It can be classified as primary (1 degree) and secondary (2 degree). AI may result in severe morbidity and mortality when undiagnosed or ineffectively treated. OBJECTIVE: To determine the etiologies of AI in Thai children. MATERIAL AND METHOD: Data of children with AI presented to the authors' pediatric endocrine service between 1982 and 2002 (20 years) were retrospectively collected and analyzed. RESULTS: AI was diagnosed by clinical and laboratory data in 73 children (31 boys and 42 girls). Sixty-two (84.9%) patients had 1degree AI while 11 (15.1%) had 2 degree AI. The majority of patients with 1 degree AI (87.1%) were diagnosed with congenital adrenal hyperplasia (CAH). Other causes of 1 degree AI were uncommon such as ACTH unresponsiveness (4.8%) and no definite diagnosis (8.1%). Most children with 1 degree AI presented with hyperpigmentation. Causes of 2 degree AI were as follows: panhypopituitarism (63.6%), isolated ACTH deficiency (9.1%), and low birth weight (27.3%). CONCLUSION: In the present study, CAH was the most common cause of 1 degree AI while panhypopituitarism was the most common cause of 2 degree AI. Other causes of AI were quite uncommon. Definite causes of AI have not yet been identified in some children. Further clinical observation and special tests including molecular studies in these children are warranted for diagnostic and prognostic importance.


Assuntos
Insuficiência Adrenal/etiologia , Adolescente , Hiperplasia Suprarrenal Congênita/complicações , Insuficiência Adrenal/epidemiologia , Criança , Pré-Escolar , Feminino , Humanos , Hiperpigmentação , Hipopituitarismo , Lactente , Recém-Nascido , Masculino , Estudos Retrospectivos , Fatores de Risco , Tailândia/epidemiologia , Fatores de Tempo
16.
Ann N Y Acad Sci ; 1135: 95-8, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18574213

RESUMO

Adolescent females who have irregular menstrual periods may have the nonclassical form of congenital adrenal hyperplasia due to a mild deficiency of steroid 21-hydroxylase (NC 21-OHD). Hyperandrogenic signs such as acne, frontal hair loss, hirsutism, and irregular menstrual periods should alert the physician to the diagnosis of NC 21-OHD. An ACTH stimulation test in which serum hormone concentrations of 17-OHP, Delta(4)-androstenedione, and testosterone are determined will assist in the diagnosis of NC 21-OHD, but the definitive diagnostic test is an analysis of the mutations in the CYP21A2 gene. Typical mutations in the CYP21A2 gene in patients with NC 21-OHD are an exon 7 or an exon 1 mutation. Once the genotype establishes the diagnosis of NC 21-OHD, treatment should be initiated. Typical treatment is dexamethasone, 0.25 mg HS, which generally reverses the hyperandrogenic signs.


Assuntos
Hiperplasia Suprarrenal Congênita/diagnóstico , Hiperplasia Suprarrenal Congênita/tratamento farmacológico , Dexametasona/administração & dosagem , Adolescente , Córtex Suprarrenal/enzimologia , Hiperplasia Suprarrenal Congênita/genética , Feminino , Humanos , Esteroide 21-Hidroxilase/genética
18.
Trends Endocrinol Metab ; 19(3): 96-9, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18294861

RESUMO

Congenital adrenal hyperplasia due to steroid 11beta-hydroxylase deficiency is a genetic disorder of steroidogenesis, transmitted as an autosomal recessive trait. It is associated with low renin hypertension, hypokalemia, hyperandrogenemia and genital ambiguity in affected females. Mutations in the CYP11B1 gene, causing 11beta-hydroxylase deficiency in the zona fasciculata in the adrenal cortex, have been identified. The indicators of congenital adrenal hyperplasia caused by 11beta-hydroxylase deficiency, include increased serum concentrations of desoxycorticosterone, 11 deoxycortisol and delta4-androstenedione, and suppressed plasma renin concentrations. The disorder is treated by administration of glucocorticoids.


Assuntos
Hiperplasia Suprarrenal Congênita/metabolismo , Esteroide 11-beta-Hidroxilase/metabolismo , Córtex Suprarrenal/metabolismo , Hiperplasia Suprarrenal Congênita/complicações , Hiperplasia Suprarrenal Congênita/genética , Glucocorticoides/uso terapêutico , Humanos , Hipertensão/etiologia , Mutação , Esteroide 11-beta-Hidroxilase/genética
19.
J Clin Endocrinol Metab ; 93(1): 182-9, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18000096

RESUMO

CONTEXT: We report herein a remarkable family in which the mother of a woman with 46,XY complete gonadal dysgenesis was found to have a 46,XY karyotype in peripheral lymphocytes, mosaicism in cultured skin fibroblasts (80% 46,XY and 20% 45,X) and a predominantly 46,XY karyotype in the ovary (93% 46,XY and 6% 45,X). PATIENTS: A 46,XY mother who developed as a normal woman underwent spontaneous puberty, reached menarche, menstruated regularly, experienced two unassisted pregnancies, and gave birth to a 46,XY daughter with complete gonadal dysgenesis. RESULTS: Evaluation of the Y chromosome in the daughter and both parents revealed that the daughter inherited her Y chromosome from her father. Molecular analysis of the genes SOX9, SF1, DMRT1, DMRT3, TSPYL, BPESC1, DHH, WNT4, SRY, and DAX1 revealed normal male coding sequences in both the mother and daughter. An extensive family pedigree across four generations revealed multiple other family members with ambiguous genitalia and infertility in both phenotypic males and females, and the mode of inheritance of the phenotype was strongly suggestive of X-linkage. CONCLUSIONS: The range of phenotypes observed in this unique family suggests that there may be transmission of a mutation in a novel sex-determining gene or in a gene that predisposes to chromosomal mosaicism.


Assuntos
Fertilidade/genética , Disgenesia Gonadal 46 XY/genética , Adolescente , DNA/química , DNA/genética , Feminino , Fertilidade/fisiologia , Humanos , Cariotipagem , Masculino , Pessoa de Meia-Idade , Linhagem , Reação em Cadeia da Polimerase , Análise de Sequência de DNA
20.
J Pediatr Endocrinol Metab ; 20(8): 883-91, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17937061

RESUMO

This retrospective study examined the pubertal characteristics and growth in patients with 21-hydroxylase deficiency (21-OHD). There were 18 males and 31 females with salt wasting (SW), simple virilizing (SV), or non-classical (NC) 21-OHD. Mean ages at onset of puberty (AOP) in SW, SV, and NC males were 9.2 +/- 1.9, 10.3 +/- 1.1, and 10.7 +/- 0.8 years, respectively; while mean AOP in SW, SV, and NC females were 9.3 +/- 1.7, 8.6 +/- 1.6, and 8.5 +/- 1.3 years, respectively. Mean final height (FH) in SW males (159.6 +/- 7.8 cm) was less than in SV (166.8 +/- 7.5 cm, p = 0.06) and NC (173.4 +/- 6.4 cm, p = 0.005) males. Mean FH in SW females (157.1 +/- 5.5 cm) was similar to SV (156.0 +/- 8.4 cm) but less than NC (161.3 +/- 5.4 cm, p = 0.01) females. In conclusion, while the patients as a group entered puberty earlier than the general population, SW males entered puberty the earliest and had the most compromised FH outcome.


Assuntos
Hiperplasia Suprarrenal Congênita/fisiopatologia , Estatura/fisiologia , Desenvolvimento Infantil/fisiologia , Puberdade/fisiologia , Maturidade Sexual/fisiologia , Adolescente , Criança , Pré-Escolar , Estudos de Coortes , Feminino , Humanos , Lactente , Estudos Longitudinais , Masculino , Estudos Retrospectivos , Fatores Sexuais , Esteroide 21-Hidroxilase/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...